Drug Description in Trials / DrugBank / KEGG DRUG /


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
116,5% Cutaquig----1件: 65
22(S)-(ACETYLAMINO)-4-METHYLPENTANOIC ACID----2件: 19, 65
336-482-Hyaluronoglucosaminidase PH20 (rHuPH20)1件: Hyaluronidase3件: D04455 ,
D04456 ,
D06604
--1件: 65
4A10BK03----1件: 65
5Abatacept1件: Abatacept1件: D03203 2件: CD80,
CD86 💬
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
6Acoziborole----1件: 65
7Acoziborole (SCYX-7158)1件: SCYX-7158---1件: 65
8ADA gene transfer----1件: 65
9ADA PBSC----1件: 65
10ADA Umbilical Cord Blood Cells----1件: 65
11Adagen1件: Pegademase1件: D05384 --1件: 65
12Adenosine1件: Adenosine1件: D00045 4件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3 💬
12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬3件: 13, 58, 65
13Administration of drug (Interferon-gamma 1-b) subcutaneously----1件: 65
14Adverse Reactions of Gammagard subcutaneously at Week 12----1件: 65
15Adverse Reactions of Gammagard subcutaneously at Week 24----1件: 65
16Adverse Reactions of Gammagard subcutaneously at Week 36----1件: 65
17Adverse Reactions of Gammagard subdermally at Week 12----1件: 65
18Adverse Reactions of Gammagard subdermally at Week 24----1件: 65
19Adverse Reactions of Gammagard subdermally at Week 36----1件: 65
20ALDESLEUKIN1件: Aldesleukin1件: D00748 3件: IL2RA,
IL2RB,
IL2RG 💬
14件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬4件: 49, 65, 96, 97
21Alefacept1件: Alefacept1件: D02800 1件: CD58 💬2件: Cell adhesion molecules, Epstein-Barr virus infection 💬6件: 37, 60, 65, 164, 284, 285
22ALEMTUZUMAB1件: Alemtuzumab1件: D02802 1件: CD52 💬-17件: 13, 15, 19, 20, 36, 43, 44, 46, 51, 60, 63, 65, 85, 96, 164, 283, 284
23Alemtuzumab 0.2 mg1件: Alemtuzumab1件: D02802 1件: CD52 💬-2件: 65, 164
24Alemtuzumab 0.3 mg1件: Alemtuzumab1件: D02802 1件: CD52 💬-2件: 65, 164
25Alentuzumab (Campath)1件: Alemtuzumab1件: D02802 1件: CD52 💬-1件: 65
26Allo BMT----1件: 65
27Allogeneic Bone Marrow Transplantation----9件: 60, 62, 65, 96, 164, 283, 284, 285, 286
28Allogeneic hematopoietic stem cell transplantation----8件: 28, 51, 60, 62, 65, 164, 284, 285
29Allogeneic HSC----1件: 65
30Allogeneic HSCT----1件: 65
31Allogeneic peripheral blood stem cell----1件: 65
32Anti-CD45----3件: 60, 65, 285
33Anti-Thymocyte Globulin----18件: 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285
34Anti-Thymocyte Globulin (Rabbit)1件: Rabbit---4件: 60, 65, 96, 285
35Antithymocyte Globulin----3件: 60, 65, 284
36AProArt----1件: 65
37Argininhydrochlorid----1件: 65
38Asceniv™----1件: 65
39Asparaginase1件: Asparaginase Escherichia coli1件: D02997 --1件: 65
40Autologous CD34+ cell transduced with G2SCID vector----1件: 65
41AUTOLOGOUS CD34+ CELLS TRANSDUCED EX-VIVO WITH THE PCCLCHIMGP91/VSVG LENTIVIRAL VECTOR----1件: 65
42Autologous CD34+ cells transduced with the Lentiviral vector containing the human Wiskott Aldrich Sy----1件: 65
43Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human Wiskott Aldrich Syndrome (WAS) cDNA sequence----1件: 65
44Autologous CD34+ HSCs transduced ex vivo with EFS lentiviral vector encoding for the human ADA gene----1件: 65
45AUTOLOGOUS CD34+CELLS TRANSDUCED WITH THE W1.6_HWASP_WPRE (VSVG) LENTIVIRAL VECTOR----1件: 65
46Autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)1件: Adenosine1件: D00045 4件: ADORA1,
ADORA2A,
ADORA2B,
ADORA3 💬
12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 65
47Azathioprine1件: Azathioprine2件: D00238 ,
D03033
--21件: 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162
48B-Lymphocyte Stimulator (BLyS)----1件: 65
49Baclofen1件: Baclofen1件: D00241 2件: GABBR1,
GABBR2 💬
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬7件: 2, 10, 13, 18, 65, 149, 206
50Bacteriophage----1件: 65
51Benznidazole1件: Benznidazole1件: D02489 --1件: 65
52Biological sampling----1件: 65
53Bivigam----1件: 65
54Blood draw----5件: 6, 19, 65, 231, 299
55Blood sample----18件: 8, 13, 46, 49, 51, 53, 61, 65, 66, 84, 96, 97, 107, 127, 235, 274, 288, 299
56BMS-188667----9件: 46, 49, 53, 65, 96, 97, 107, 222, 271
57BPX-501 T cells----4件: 65, 284, 285, 326
58BT090----1件: 65
59BT524----1件: 65
60BT595----2件: 63, 65
61BT681----1件: 65
62BUSILVEX1件: Busulfan1件: D00248 --4件: 19, 36, 60, 65
63BUSILVEX - 6 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 10 ML 8 FLACONCINI1件: Busulfan1件: D00248 --2件: 19, 65
64Busulfan1件: Busulfan1件: D00248 --13件: 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326
65Busulfan IV1件: Busulfan1件: D00248 --1件: 65
66Busulfan test dose1件: Busulfan1件: D00248 --1件: 65
67Busulfan, Cyclophosphamide, ATG, GCSF2件: Busulfan,
Cyclophosphamide
3件: D00248 ,
D00287 ,
D07760
--2件: 65, 284
68Busulfan, Fludarabine and ATG2件: Busulfan,
Fludarabine
3件: D00248 ,
D01907 ,
D07966
1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬1件: 65
69Busulfan, Fludarabine, ATG, TLI2件: Busulfan,
Fludarabine
3件: D00248 ,
D01907 ,
D07966
1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬2件: 65, 284
70C1 ESTERASE INHIBITOR (HUMAN)1件: Human C1-esterase inhibitor---1件: 65
71C1 Esterase Inhibitor Human1件: Human C1-esterase inhibitor---1件: 65
72C1 inhibitor1件: Human C1-esterase inhibitor---1件: 65
73C1 inhibitor concentrate1件: Human C1-esterase inhibitor---1件: 65
74C1-esterase inhibitor [recombinant] (C1-INH-R)1件: Human C1-esterase inhibitor---1件: 65
75C1-INH1件: Human C1-esterase inhibitor---1件: 65
76Campath1件: Alemtuzumab1件: D02802 1件: CD52 💬-12件: 19, 20, 49, 51, 60, 62, 65, 164, 234, 283, 285, 326
77Campath -1H1件: Alemtuzumab1件: D02802 1件: CD52 💬-1件: 65
78Campath 1H1件: Alemtuzumab1件: D02802 1件: CD52 💬-4件: 60, 65, 164, 285
79Campath, Fludarabine, Cyclophosphamide2件: Cyclophosphamide,
Fludarabine
4件: D00287 ,
D01907 ,
D07760 ,
D07966
1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬2件: 65, 284
80Catapresan----2件: 65, 78
81Catapresan 75, Tabletten----1件: 65
82CD3/CD19 neg allogeneic BMT----1件: 65
83CD3/CD19 negative allogeneic hematopoietic stem cells----1件: 65
84CD34 Stem Cell Selection Therapy----3件: 60, 65, 284
85CD34+----1件: 65
86CD34+ cells transduced with ADA retrovir----1件: 65
87CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1a-h?c-OPT----1件: 65
88CD34+CELLS----2件: 65, 285
89CDZ173----2件: 53, 65
90Cell processing for TCRabeta+/CD19+ depletion----1件: 65
91Cell processing for TCRaß+/CD19+ depletion----1件: 65
92Chemotherapy, intrathecal chemotherapy, steroid therapy----1件: 65
93Chloride1件: Chloride ion---29件: 6, 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 67, 78, 96, 97, 107, 127, 168, 171, 193, 227, 228, 251, 271, 288, 296, 297, 299, 338
94Chrono Super PID then Generic Syringe-Gammanorm----1件: 65
95CliniMACS----2件: 60, 65
96CliniMACS® CD34 Reagent System cell sorter device----1件: 65
97Clonidine1件: Clonidine2件: D00281 ,
D00604
3件: ADRA2A,
ADRA2B,
ADRA2C 💬
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬4件: 6, 65, 70, 78
98Clonidinhydrochlorid----1件: 65
99Collection of samples----4件: 49, 65, 95, 107
100Conjugated pneumococcal vaccine (Prevenar)----1件: 65
101Continuous Glucose Monitor2件: Dextrose, unspecified form,
Methamidophos
---1件: 65
102COVID-19 Vaccine Moderna1件: Moderna COVID-19 Vaccine1件: D12114 --4件: 46, 51, 65, 299
103Cryopreserved EFS-ADA LV transduced patient CD34+ cells----1件: 65
104Cryopreserved G2SCID lentiviral vector transduced patient CD34+ cells----1件: 65
105CT Scan----1件: 65
106Cultured Thymus Tissue----1件: 65
107Cultured Thymus Tissue for Implantation (CTTI)----1件: 65
108Cultured Thymus Tissue Implantation (CTTI)----1件: 65
109CUTAQUIG----1件: 65
110CUVITRU----1件: 65
111Cuvitru 200 mg/ml solution for subcutaneous injection1件: Human immunoglobulin G---1件: 65
112Cyclophosphamide1件: Cyclophosphamide2件: D00287 ,
D07760
--45件: 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 265, 274, 283, 284, 285, 288, 326, 331
113Cyclophosphamide (Cytoxan)1件: Cyclophosphamide2件: D00287 ,
D07760
--1件: 65
114Cyclophosphamide 301件: Cyclophosphamide2件: D00287 ,
D07760
--3件: 65, 285, 326
115Cyclophosphamide 401件: Cyclophosphamide2件: D00287 ,
D07760
--3件: 65, 285, 326
116Cyclophosphamide Dose Level 11件: Cyclophosphamide2件: D00287 ,
D07760
--2件: 65, 284
117Cyclophosphamide Dose Level 21件: Cyclophosphamide2件: D00287 ,
D07760
--2件: 65, 284
118Cyclophosphamide Dose Level 31件: Cyclophosphamide2件: D00287 ,
D07760
--2件: 65, 284
119Cyclophosphamide Dose Level 41件: Cyclophosphamide2件: D00287 ,
D07760
--2件: 65, 284
120Cyclophosphamide post transplant1件: Cyclophosphamide2件: D00287 ,
D07760
--1件: 65
121Cyclosporine1件: Cyclosporine1件: D00184 5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬
33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬37件: 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 107, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302
122Cyclosporins----4件: 53, 60, 65, 222
123Cytarabine1件: Cytarabine3件: D00168 ,
D03046 ,
D03637
--7件: 11, 13, 14, 25, 49, 60, 65
124DACLIZUMAB1件: Daclizumab1件: D03639 1件: IL2RA 💬11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬8件: 13, 56, 60, 65, 97, 107, 283, 284
125Danazol1件: Danazol1件: D00289 3件: AR,
ESR1,
PGR 💬
12件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬5件: 60, 63, 64, 65, 285
126Data collection----1件: 65
127Daunorubicin1件: Daunorubicin2件: D01264 ,
D07776
2件: TOP2A,
TOP2B 💬
1件: Platinum drug resistance 💬1件: 65
128DB289----1件: 65
129Depletion in CD45RA graft donor----1件: 65
130Dexametasone Fosfato Sodico----1件: 65
131Dexamethasone1件: Dexamethasone9件: D00292 ,
D00975 ,
D01510 ,
D01615 ,
D01632 ,
D01948 ,
D02174 ,
D02591 ,
D02592
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬25件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
132Dexamethasone 21-dihydrogen phosphate3件: Dexamethasone,
Hydrogen,
Phosphate ion
9件: D00292 ,
D00975 ,
D01510 ,
D01615 ,
D01632 ,
D01948 ,
D02174 ,
D02591 ,
D02592
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 65
133DEXAMETHASONE SODIUM PHOSPHATE2件: Dexamethasone,
Phosphate ion
9件: D00292 ,
D00975 ,
D01510 ,
D01615 ,
D01632 ,
D01948 ,
D02174 ,
D02591 ,
D02592
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬3件: 65, 70, 96
134Dexamethasone sodium phosphate (soluzione 25mg/ml)2件: Dexamethasone,
Phosphate ion
9件: D00292 ,
D00975 ,
D01510 ,
D01615 ,
D01632 ,
D01948 ,
D02174 ,
D02591 ,
D02592
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 65
135DEXAMETHASONE SODIUM PHOSPHATE PH. EUR.2件: Dexamethasone,
Phosphate ion
9件: D00292 ,
D00975 ,
D01510 ,
D01615 ,
D01632 ,
D01948 ,
D02174 ,
D02591 ,
D02592
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 65
136Dexamethasone, procarbazine2件: Dexamethasone,
Procarbazine
11件: D00292 ,
D00478 ,
D00975 ,
D01510 ,
D01615 ,
D01632 ,
D01948 ,
D02174 ,
D02591 ,
D02592 ,
D08423
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 65
137Dextrose1件: Dextrose, unspecified form---5件: 56, 60, 65, 70, 226
138Dextrose, 5% in Water2件: Dextrose, unspecified form,
Water
1件: D00001 --1件: 65
139Diagnostic Test: blood drawing in healthy controls----1件: 65
140Diagnostic Test: blood drawing in patients with WAS----1件: 65
141Diagnostic Test: functional and antigenic C1 inhibitor1件: Human C1-esterase inhibitor---1件: 65
142Diagnostic Test: Oral glucose tolerance test1件: Dextrose, unspecified form---3件: 13, 65, 299
143Diagnostic Test: RNA and neopterin detection1件: Neopterin---1件: 65
144Dihydrogen1件: Hydrogen---1件: 65
145Donor peripheral blood stem cells.----1件: 65
146Doxorubicin1件: Doxorubicin1件: D03899 2件: TOP2A,
TOP2B 💬
1件: Platinum drug resistance 💬5件: 26, 28, 34, 65, 331
147Doxorubicin, methotrexate, cyclophosphamide, L-asparaginase4件: Asparaginase Escherichia coli,
Cyclophosphamide,
Doxorubicin,
Methotrexate
6件: D00142 ,
D00287 ,
D02115 ,
D02997 ,
D03899 ,
D07760
4件: DHFR,
DHFR2,
TOP2A,
TOP2B 💬
6件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate, Platinum drug resistance 💬1件: 65
148EDS-EP dose range of ~14-22 mg DSP/infusion----1件: 65
149EDS-EP dose range of ~5-10 mg DSP/infusion----1件: 65
150EF1aS-ADA lentiviral vector gene modified autologous CD34+ cells----1件: 65
151EF1aS-ADA lentiviral vector transduced patient CD34+ cells----1件: 65
152Efficacy of Gammagard subcutaneously at Week 12----1件: 65
153Efficacy of Gammagard subcutaneously at Week 24----1件: 65
154Efficacy of Gammagard subcutaneously at Week 36----1件: 65
155Efficacy of Gammagard subdermally at Week 12----1件: 65
156Efficacy of Gammagard subdermally at Week 24----1件: 65
157Efficacy of Gammagard subdermally at Week 36----1件: 65
158Eflornithine1件: Eflornithine1件: D07883 1件: ODC1 💬3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬1件: 65
159Eflornithine plus Nifurtimox combination therapy2件: Eflornithine,
Nifurtimox
2件: D00833 ,
D07883
1件: ODC1 💬3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬1件: 65
160Elapegademase1件: Elapegademase1件: D11017 1件: ADA 💬3件: Metabolic pathways, Primary immunodeficiency, Purine metabolism 💬1件: 65
161Elapegademase-lvlr1件: Elapegademase1件: D11017 1件: ADA 💬3件: Metabolic pathways, Primary immunodeficiency, Purine metabolism 💬1件: 65
162ELTROMBOPAG1件: Eltrombopag---5件: 60, 63, 65, 284, 285
163Empagliflozin1件: Empagliflozin1件: D10459 1件: SLC5A2 💬-5件: 65, 72, 96, 97, 257
164EP2006----1件: 65
165EP2006 (Filgrastim)1件: Filgrastim1件: D03235 1件: CSF3R 💬5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬1件: 65
166Estradiol1件: Estradiol8件: D00105 ,
D01413 ,
D01617 ,
D01953 ,
D04061 ,
D04063 ,
D04064 ,
D04065
2件: ESR1,
ESR2 💬
10件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬7件: 13, 46, 49, 65, 76, 226, 299
167Estradiol valerate2件: Estradiol,
Estradiol valerate
8件: D00105 ,
D01413 ,
D01617 ,
D01953 ,
D04061 ,
D04063 ,
D04064 ,
D04065
2件: ESR1,
ESR2 💬
10件: Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬1件: 65
168Estradiolvalerat----1件: 65
169Etoposide1件: Etoposide2件: D00125 ,
D04107
2件: TOP2A,
TOP2B 💬
1件: Platinum drug resistance 💬11件: 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331
170Etoposide, cytarabine, mercaptopurine3件: Cytarabine,
Etoposide,
Mercaptopurine
7件: D00125 ,
D00161 ,
D00168 ,
D03046 ,
D03637 ,
D04107 ,
D04931
3件: HPRT1,
TOP2A,
TOP2B 💬
4件: Drug metabolism - other enzymes, Metabolic pathways, Platinum drug resistance, Purine metabolism 💬1件: 65
171Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector----1件: 65
172EZN-2279----1件: 65
173Fansidar (pyrimethamine and sulfadoxine)1件: Pyrimethamine1件: D00488 --1件: 65
174Fexinidazole1件: Fexinidazole1件: D11252 --1件: 65
175Fibrinogen1件: Fibrinogen human---3件: 14, 65, 288
176Fibrinogen (coagulation factorI)1件: Fibrinogen human---1件: 65
177Fibrinogen Concentrate from Human Plasma1件: Fibrinogen human---1件: 65
178Filgrastim1件: Filgrastim1件: D03235 1件: CSF3R 💬5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬28件: 2, 6, 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331
179Filgrastim Hexal1件: Filgrastim1件: D03235 1件: CSF3R 💬5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬1件: 65
180Filgrastim, Alemtuzumab2件: Alemtuzumab,
Filgrastim
2件: D02802 ,
D03235
2件: CD52,
CSF3R 💬
-1件: 65
181Flebogamma 5% DIF----1件: 65
182Fludarabina1件: Fludarabine2件: D01907 ,
D07966
1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬2件: 19, 65
183Fludarabina Accord1件: Fludarabine2件: D01907 ,
D07966
1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬1件: 65
184FLUDARABINA TEVA - 25 MG/ML CONCENTRATO PER SOLUZIONE INIETTABILE O PER INFUSIONE 1 FLACONCINO DI VETRO DA 2 ML1件: Fludarabine2件: D01907 ,
D07966
1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬1件: 65
185Fludarabine1件: Fludarabine2件: D01907 ,
D07966
1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬18件: 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326
186Fludarabine monophosphate1件: Fludarabine2件: D01907 ,
D07966
1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬3件: 65, 284, 326
187Fludarabine phosphate2件: Fludarabine,
Phosphate ion
2件: D01907 ,
D07966
1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬12件: 28, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285, 286
188Fludarabine phosphate 30 mg2件: Fludarabine,
Phosphate ion
2件: D01907 ,
D07966
1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬2件: 65, 164
189Fludarabine phosphate 40 mg2件: Fludarabine,
Phosphate ion
2件: D01907 ,
D07966
1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬2件: 65, 164
190Fludarabine, Busulfan, Thymoglobulin3件: Antithymocyte immunoglobulin (rabbit),
Busulfan,
Fludarabine
3件: D00248 ,
D01907 ,
D07966
1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬1件: 65
191Fludarabine, Melphalan, Thiotepa3件: Fludarabine,
Melphalan,
Thiotepa
4件: D00369 ,
D00583 ,
D01907 ,
D07966
1件: RRM1 💬5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬1件: 65
192FORTECORTIN----2件: 28, 65
193Fortecortin Inject 40 mg Amp.----1件: 65
194Fucose1件: Fucose---1件: 65
195G-CSF1件: Filgrastim1件: D03235 1件: CSF3R 💬5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬16件: 2, 6, 11, 13, 16, 47, 49, 51, 60, 62, 65, 85, 96, 284, 285, 331
196G-CSF for Conditioning before HSCT.1件: Filgrastim1件: D03235 1件: CSF3R 💬5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬1件: 65
197G1XCG----1件: 65
198G1XCGD transduced CD34+ cells----1件: 65
199Gadolinium1件: Gadolinium---6件: 13, 34, 46, 58, 65, 86
200Gadolinium For abdomen1件: Gadolinium---1件: 65
201Gadolinium For lower back1件: Gadolinium---1件: 65
202GAMMAGARD LIQUID----1件: 65
203Gammagard S/D (Solvent/Detergent)----1件: 65
204Gammaglobulin----1件: 65
205Gammanorm----2件: 14, 65
206Gammanorm 165 mg/mL----1件: 65
207Gammaplex----2件: 63, 65
208Gammaplex (5%)----1件: 65
209Gammaplex (Intravenous immunoglobulin)----1件: 65
210Gammaplex 101件: Human immunoglobulin G---1件: 65
211GAMUNEX-C----1件: 65
212Gcsf----1件: 65
213Gene Therapy Method for CGD----1件: 65
214Gene transfer----1件: 65
215Gene-Transduced Autologous CD34+ Stem Cells----1件: 65
216Generic Syringe then Chrono Super PID-Gammanorm----1件: 65
217Genetic: CL20-i4-EF1a-h?c-OPT----1件: 65
218Genetic: Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)----1件: 65
219Genetic: Infusion of autologous EFS-ADA LV CD34+ (OTL-101)----1件: 65
220Genetic: Infusion of autologous EFS-ADA LV CD34+ cells----1件: 65
221Genetically modified autologous blood stem cells----1件: 65
222Glucose1件: Dextrose, unspecified form---15件: 2, 6, 13, 49, 50, 65, 75, 86, 88, 96, 160, 195, 254, 257, 299
223Glycolic acid1件: Glycolic acid---1件: 65
224Glycosade----3件: 65, 256, 257
225Gold1件: Gold---43件: 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 171, 193, 218, 222, 224, 227, 230, 235, 271, 291, 294, 296, 298, 299, 310, 318
226Gp91 Grans----1件: 65
227Granulocyte Colony Stimulating Factor1件: Filgrastim1件: D03235 1件: CSF3R 💬5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬6件: 2, 28, 36, 57, 65, 85
228Granulocyte colony stimulating factor (G-CSF)1件: Filgrastim1件: D03235 1件: CSF3R 💬5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬1件: 65
229GTG003.08----1件: 65
230GVHD Prophylaxis----2件: 60, 65
231Haemocomplettan P----1件: 65
232Haemocomplettan(R) P----1件: 65
233Haemocomplettan(R) P 1g/2g----1件: 65
234Haplo BM with T cell depletion----1件: 65
235Haploidentical Hematopoietic Cell Transplantation----2件: 60, 65
236Hematopoetic Stem Cell Transplantation----5件: 19, 65, 120, 160, 326
237Hematopoietic Stem Cell Transplant----2件: 65, 285
238Hematopoietic Stem Cell Transplantation----13件: 11, 13, 14, 19, 20, 35, 46, 49, 51, 65, 96, 234, 285
239Hizentra1件: Human immunoglobulin G---4件: 14, 50, 51, 65
240Hizentra®1件: Human immunoglobulin G---2件: 14, 65
241Horse -Anti-thymocyte----1件: 65
242HTLP----1件: 65
243HUMAN FIBRINOGEN1件: Fibrinogen human---1件: 65
244Human Fibrinogen Concentrate1件: Fibrinogen human---1件: 65
245Human Immunglobulin G (IgG)----1件: 65
246Human Immunoglobulin----2件: 63, 65
247HUMAN IMMUNOGLOBULIN G1件: Human immunoglobulin G---4件: 14, 50, 63, 65
248Human normal immunoglobulin1件: Human immunoglobulin G---9件: 11, 13, 14, 43, 45, 50, 51, 63, 65
249HUMAN NORMAL IMMUNOGLOBULIN (IV)1件: Human immunoglobulin G---4件: 11, 14, 63, 65
250Human normal immunoglobulin (IVIg)1件: Human immunoglobulin G---3件: 14, 50, 65
251Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)1件: Human immunoglobulin G---1件: 65
252Human normal immunoglobulin (subcutaneous)1件: Human immunoglobulin G---1件: 65
253HUMAN NORMAL IMMUNOGLOBULIN FOR1件: Human immunoglobulin G---1件: 65
254Human normal immunoglobulin for intravenous administration1件: Human immunoglobulin G---3件: 14, 51, 65
255HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE1件: Human immunoglobulin G---2件: 63, 65
256Human normal immunoglobulin for intravenous use (IVIG)1件: Human immunoglobulin G---1件: 65
257Human normal immunoglobulin for subcutaneous administration1件: Human immunoglobulin G---2件: 51, 65
258Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)1件: Human immunoglobulin G---1件: 65
259Human normal immunoglobulin G (IgG > 98% purity)1件: Human immunoglobulin G---3件: 14, 63, 65
260Human T Lymphoid Progenitor (HTLP) injection----1件: 65
261Hyaluronidase1件: Hyaluronidase3件: D04455 ,
D04456 ,
D06604
--5件: 14, 28, 51, 65, 331
262Hyaluronoglucosaminidase1件: Hyaluronidase3件: D04455 ,
D04456 ,
D06604
--1件: 65
263Hydroxyurea1件: Hydroxyurea1件: D00341 1件: RRM2 💬6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway 💬8件: 3, 13, 19, 20, 65, 85, 86, 284
264HyQvia1件: Hyaluronidase (human recombinant)---2件: 14, 65
265HyQvia 100 mg/ml solution for infusion for subcutaneous use1件: Human immunoglobulin G---1件: 65
266I10E----3件: 14, 63, 65
267IB 1001----1件: 65
268IB1001----2件: 19, 65
269Ibuprofen1件: Ibuprofen4件: D00126 ,
D01122 ,
D04490 ,
D06606
2件: PTGS1,
PTGS2 💬
23件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬7件: 13, 46, 65, 107, 113, 271, 299
270IFN-gamma----1件: 65
271Ig VENA 50 g/l solution for infusion 100 ml vial + infusion set----2件: 63, 65
272IgG Next Generation----2件: 63, 65
273IgG Next Generation (BT595)----1件: 65
274IgHy10----1件: 65
275IGIV, 10%----2件: 14, 65
276IGIV-C 10%----1件: 65
277IgNextGen 16%----1件: 65
278IGNG----1件: 65
279IgPro10----3件: 14, 51, 65
280IgPro20----4件: 14, 50, 51, 65
281IGSC 20%----1件: 65
282IGSC 20% 150 mg/kg----1件: 65
283IGSC 20% daily push versus 2 times per week pump----1件: 65
284IGSC 20% daily push versus every 2 weeks pump----1件: 65
285IGSC 20% daily push versus once a week pump----1件: 65
286IGSC 20% infusion----1件: 65
287IGSC, 16%----1件: 65
288IGSC, 20%----1件: 65
289Immune Globulin Infusion (Human), 10%----1件: 65
290Immune Globulin Intravenous----1件: 65
291Immune Globulin Intravenous (Human)----1件: 65
292Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™----1件: 65
293Immune Globulin Intravenous (human), 10%----2件: 14, 65
294Immune Globulin Intravenous (Human), 10% Solution----1件: 65
295Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution----1件: 65
296Immune Globulin Intravenous (IGIV)----1件: 65
297Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified----1件: 65
298Immune Globulin Subcutaneos, 20%1件: Human immunoglobulin G---1件: 65
299Immune Globulin Subcutaneous (Human)----2件: 14, 65
300Immune Globulin Subcutaneous (Human) (SCIG)----1件: 65
301Immune Globulin Subcutaneous (Human), 20%1件: Human immunoglobulin G---1件: 65
302Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (IGSC 20%)----1件: 65
303Immune Globulin Subcutaneous (Human), 20% Solution----1件: 65
304Immune Globulin Subcutaneous (Human), 20%, Caprylate/Chromatography Purified----1件: 65
305Immune Globulin Subcutaneous, 20%1件: Human immunoglobulin G---1件: 65
306Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)----1件: 65
307Immunglobulin (human)----1件: 65
308IMMUNOGLOBULIN G----8件: 2, 11, 13, 14, 49, 50, 63, 65
309Immunoglobulin G (Ig NextGen 16%)----1件: 65
310Immunoglobulin intravenous (human)1件: Human immunoglobulin G---1件: 65
311IMMUNOGLOBULINA UMANA NORMALE----2件: 51, 65
312Immunoglobulins Intravenous (Human)----1件: 65
313Immunoglobulins, normal human----1件: 65
314Immunological diagnosis tests----1件: 65
315Immunosuppression Only Conditioning----1件: 65
316Immunosuppression Only Conditioning -Closed with amendment L----1件: 65
317In vitro-treated peripheral blood stem cell transplantation----2件: 60, 65
318Increlex1件: Mecasermin2件: D03297 ,
D04870
2件: GHR,
IGF1R 💬
33件: AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬4件: 65, 78, 96, 299
319Infliximab1件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬26件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
320INH----1件: 65
321Interferon Gamma1件: Interferon Gamma---8件: 18, 65, 85, 107, 228, 299, 301, 326
322INTERFERON GAMMA-1B2件: Interferon Gamma,
Interferon gamma-1b
1件: D00747 2件: IFNGR1,
IFNGR2 💬
18件: Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬7件: 18, 65, 85, 228, 299, 301, 326
323Interferon-gamma----1件: 65
324INTERLEUKIN-21件: Human interleukin-2---8件: 2, 35, 49, 55, 65, 96, 97, 162
325Intratect----4件: 13, 14, 35, 65
326Intravenous immunoglobulin infusion----1件: 65
327Intravenous infusion of transduced cells----1件: 65
328Isolex 300i Magnetic Cell Selector----1件: 65
329Itraconazole1件: Itraconazole1件: D00350 --5件: 3, 65, 96, 227, 299
330IV treatment with IGSC, 10%----1件: 65
331IVIG1件: Human immunoglobulin G---8件: 11, 13, 14, 17, 35, 50, 51, 65
332IVIG-PEG----1件: 65
333Jardiance1件: Empagliflozin1件: D10459 1件: SLC5A2 💬-1件: 65
334Kedrion IVIG 10%----1件: 65
335KIg10----1件: 65
336Kineret1件: Anakinra1件: D02934 2件: IL1R1,
IL1R2 💬
15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬9件: 28, 41, 46, 49, 65, 106, 107, 266, 299
337KIOVIG1件: Human immunoglobulin G---2件: 14, 65
338KIOVIG 100 mg/ml solution for infusion1件: Human immunoglobulin G---2件: 14, 65
339KLH----2件: 13, 65
340KVD824----1件: 65
341KVD824 300 mg Compresse a rilascio modificato----1件: 65
342KVD824 300 mg Modified Release Tablets1件: Manganese citrate---1件: 65
343KVD824 hydrochloride----1件: 65
344KVD900----1件: 65
345KVD900 100 mg Film Coated Tablet----1件: 65
346KVD900 300 mg----1件: 65
347KVD900 600 mg----1件: 65
348L-Arginin1件: Arginine1件: D02982 --1件: 65
349L-Arginin-hydrochlorid-einmolar Fresenius1件: Arginine1件: D02982 --1件: 65
350L-asparaginase1件: Asparaginase Escherichia coli1件: D02997 --1件: 65
351L-fucose1件: Fucose---1件: 65
352LADICell----1件: 65
353Lapine T-Lymphocyte Immune Globulin1件: Antithymocyte immunoglobulin (rabbit)---4件: 62, 65, 283, 286
354LDT----1件: 65
355Lemtrada1件: Alemtuzumab1件: D02802 1件: CD52 💬-2件: 13, 65
356Leniolisib1件: Leniolisib1件: D11158 3件: PIK3CA,
PIK3CB,
PIK3CD 💬
106件: AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬2件: 53, 65
357Lenograstim1件: Lenograstim1件: D03247 1件: CSF3R 💬5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬7件: 2, 13, 16, 18, 19, 57, 65
358Lentiviral G1XCGD Gene Therapy----1件: 65
359Lentiviral vector transduced CD34+ cells----1件: 65
360Leucine1件: Leucine1件: D00030 --11件: 5, 6, 7, 19, 65, 96, 97, 127, 283, 284, 299
361LFB-IgSC----1件: 65
362MabThera1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬22件: 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271
363MABTHERA - 2 FIALE 100 MG 10 ML1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬2件: 19, 65
364Mavorixafor----1件: 65
365MBM-01----1件: 65
366MCTLs----1件: 65
367Melarsoprol1件: Melarsoprol1件: D00832 --1件: 65
368Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d2件: Eflornithine,
Melarsoprol
2件: D00832 ,
D07883
1件: ODC1 💬3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬1件: 65
369Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d2件: Melarsoprol,
Nifurtimox
2件: D00832 ,
D00833
--1件: 65
370Melphalan1件: Melphalan1件: D00369 --15件: 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285, 299
371Mercaptopurine1件: Mercaptopurine2件: D00161 ,
D04931
1件: HPRT1 💬3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬4件: 65, 96, 97, 164
372Mesna1件: Coenzyme M---11件: 11, 13, 44, 45, 49, 51, 60, 65, 85, 96, 164
373Metformin1件: Metformin2件: D00944 ,
D04966
2件: PRKAA1,
PRKAA2 💬
20件: AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬24件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
374Methotrexate1件: Methotrexate2件: D00142 ,
D02115
2件: DHFR,
DHFR2 💬
5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
375Methylprednisolone1件: Methylprednisolone6件: D00407 ,
D00751 ,
D00979 ,
D05000 ,
D05001 ,
D05002
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬48件: 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
376Methylprednisolone or Prednisolone2件: Methylprednisolone,
Prednisolone
14件: D00407 ,
D00472 ,
D00751 ,
D00979 ,
D00980 ,
D00981 ,
D00982 ,
D01239 ,
D01998 ,
D02156 ,
D03301 ,
D05000 ,
D05001 ,
D05002
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 65
377Miltenyi CliniMACS----3件: 62, 65, 285
378Miltenyi CliniMACS selection system----1件: 65
379MMF----15件: 13, 35, 40, 46, 49, 50, 51, 60, 65, 66, 162, 222, 224, 226, 299
380MONITOR1件: Methamidophos---20件: 2, 11, 13, 19, 28, 46, 49, 58, 65, 70, 81, 85, 86, 98, 113, 118, 129, 298, 299, 300
381Mozobil1件: Plerixafor1件: D08971 1件: CXCR4 💬12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor 💬3件: 19, 65, 285
382MOZOBIL - 20 MG/ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 24 MG/1.2 ML 1 FLACONCINO1件: Plerixafor1件: D08971 1件: CXCR4 💬12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor 💬1件: 65
383Mozobil 20mg/mL vial (injectable solution for subcutaneous use)1件: Plerixafor1件: D08971 1件: CXCR4 💬12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor 💬1件: 65
384Mozobil 20mg/mL vial (injectable solution, subcutaneous use)1件: Plerixafor1件: D08971 1件: CXCR4 💬12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor 💬1件: 65
385Mozobil,1件: Plerixafor1件: D08971 1件: CXCR4 💬12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor 💬1件: 65
386Mycophenolate1件: Mycophenolic acid1件: D05096 2件: IMPDH1,
IMPDH2 💬
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬36件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300
387Mycophenolate mofetil2件: Mycophenolate mofetil,
Mycophenolic acid
4件: D00752 ,
D05094 ,
D05095 ,
D05096
2件: IMPDH1,
IMPDH2 💬
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬34件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
388Mycophenolate mofetil (MMF)2件: Mycophenolate mofetil,
Mycophenolic acid
4件: D00752 ,
D05094 ,
D05095 ,
D05096
2件: IMPDH1,
IMPDH2 💬
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬7件: 13, 49, 51, 60, 65, 66, 222
389Myeloablative Conditioning-Closed with amendment L----1件: 65
390Myeloablative Preparative Regimen----3件: 62, 65, 284
391MYELOSTIM----1件: 65
392MYELOSTIM - 34 1 FLACONCINO LIOFILIZZATO 33.6 MIU + SIRINGA PRERIEMPITA SOLVENTE 1 ML----2件: 19, 65
393MYELOSTIM 34 milions UI/ml - powder and solvent for solution for injection/infusion----1件: 65
394MYELOSTIM 34 milions UI/ml, powder and solvent for solution for injection or infusion----1件: 65
395N-Acetyl-L-Leucine1件: Leucine1件: D00030 --2件: 19, 65
396Nanogam 100 mg/ml----1件: 65
397Nanogam® 50 mg/ml----1件: 65
398NDV-3A----1件: 65
399Neopterin1件: Neopterin---1件: 65
400NewGam----3件: 14, 63, 65
401Newnorm----1件: 65
402Nicotinamide1件: Nicotinamide1件: D00036 --8件: 2, 6, 18, 49, 65, 107, 162, 191
403Nicotinamide ribonucleoside1件: Nicotinamide1件: D00036 --1件: 65
404Nifurtimox1件: Nifurtimox1件: D00833 --1件: 65
405Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d2件: Eflornithine,
Nifurtimox
2件: D00833 ,
D07883
1件: ODC1 💬3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬1件: 65
406Nifurtimox-Eflronithine Combination Treatment (NECT)1件: Nifurtimox1件: D00833 --1件: 65
407None----16件: 6, 46, 51, 65, 78, 84, 85, 96, 97, 140, 160, 161, 171, 231, 271, 299
408Nonmyeloablative allogeneic hematopoietic stem cell transplantation----6件: 28, 51, 60, 62, 65, 285
409Normal human immunoglobulin G1件: Human immunoglobulin G---1件: 65
410Norovirus -specific T-cell (NST) therapy----1件: 65
411Noxafil1件: Posaconazole1件: D02555 --3件: 60, 65, 299
412Noxafil 40 mg/ml oral solution1件: Posaconazole1件: D02555 --1件: 65
413NutropinAq 10mg/2ml (30 I.E.) Injektionsllösung1件: Somatotropin1件: D02691 1件: GHR 💬5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬1件: 65
414OCTA-C1-INH1件: Human C1-esterase inhibitor---1件: 65
415Octagam----2件: 13, 65
416Octagam 10%----3件: 50, 63, 65
417Octagam 5%----2件: 13, 65
418OCTAGAM 50 mg/ml oldatos infúzió----1件: 65
419Octanorm----2件: 50, 65
420Octanorm 16.5%----2件: 50, 65
421OMALIZUMAB1件: Omalizumab1件: D05251 1件: FCER1A 💬4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬7件: 46, 53, 65, 98, 162, 226, 299
422Omalizumab (Xolair)1件: Omalizumab1件: D05251 1件: FCER1A 💬4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬1件: 65
423ORENCIA1件: Abatacept1件: D03203 2件: CD80,
CD86 💬
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬14件: 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 160, 222, 271
424ORENCIA® 125 mg solution for injection in pre-filled syringe1件: Abatacept1件: D03203 2件: CD80,
CD86 💬
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 65
425Other hematological Agents----1件: 65
426Other:----2件: 2, 65
427Other: 0.9% sodium chloride2件: Chloride ion,
Sodium chloride
1件: D02056 --1件: 65
428Other: Blood sampling for Laboratory Developed Test (LDT) analysis----1件: 65
429Other: Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation----1件: 65
430Other: Cultured Thymus Tissue Implantation with Parathyroid Transplantation----1件: 65
431Other: Donor Lymphocyte Infusion----1件: 65
432Other: Food Diary----1件: 65
433Other: Haematopoietic Stem Cell Transplantation (HSCT)----1件: 65
434Other: Laboratory Biomarker Analysis----21件: 11, 13, 14, 26, 28, 34, 49, 51, 60, 62, 65, 89, 96, 97, 205, 232, 283, 284, 285, 298, 331
435Other: Medical History Questionnaires----1件: 65
436Other: Modified Mixed Meal Tolerance Test----1件: 65
437Other: Modified Oral Glucose Tolerance Test1件: Dextrose, unspecified form---1件: 65
438Other: Palliative Care----5件: 19, 65, 120, 160, 326
439Other: Quality-of-Life Assessment----9件: 34, 36, 51, 62, 65, 96, 283, 286, 298
440OTL-101----1件: 65
441OTL-103----1件: 65
442OTL-103 Dispersion for Infusion----1件: 65
443OVASTAT1件: Treosulfan1件: D07253 --2件: 13, 65
444Ovastat 10001件: Treosulfan1件: D07253 --2件: 13, 65
445Ovastat 1000 (Treosulfan injection)1件: Treosulfan1件: D07253 --1件: 65
446Ovastat 1000 mg, powder for solution for infusion1件: Treosulfan1件: D07253 --1件: 65
447Ovastat 50001件: Treosulfan1件: D07253 --2件: 13, 65
448Ovastat 5000 (Treosulfan injection)1件: Treosulfan1件: D07253 --1件: 65
449Ovastat 5000 mg, powder for solution for infusion1件: Treosulfan1件: D07253 --1件: 65
450Palifermin1件: Palifermin1件: D05338 1件: FGFR2 💬13件: Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells 💬5件: 13, 36, 38, 39, 65
451Pantoprazole1件: Pantoprazole2件: D02593 ,
D05353
2件: ATP4A,
ATP4B 💬
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬2件: 13, 65
452Pantoprazolo 20 mg gastro-resistant tablets----1件: 65
453PEG----12件: 6, 13, 41, 46, 65, 78, 96, 97, 140, 144, 240, 299
454Peg-Ada----1件: 65
455PEG-ADA ERT----1件: 65
456PEG-interleukin-21件: Human interleukin-2---1件: 65
457Pentamidine1件: Pentamidine2件: D00834 ,
D08333
--2件: 61, 65
458Peripheral Blood Stem Cell Transplantation----12件: 11, 13, 14, 28, 51, 60, 62, 65, 283, 284, 285, 286
459Peripheral Blood Stem Cells----2件: 51, 65
460PHA-022121----1件: 65
461Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells----1件: 65
462Phosphate1件: Phosphate ion---33件: 2, 3, 6, 11, 12, 13, 15, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 238, 256, 276, 283, 284, 285, 286, 299
463PHVS416----1件: 65
464PID----1件: 65
465Pioglitazone1件: Pioglitazone2件: D00945 ,
D08378
1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
466PLERIXAFOR1件: Plerixafor1件: D08971 1件: CXCR4 💬12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor 💬5件: 20, 51, 65, 285, 299
467Plerixafor for Conditioning before HSCT.1件: Plerixafor1件: D08971 1件: CXCR4 💬12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor 💬1件: 65
468PnCJ PPS----1件: 65
469PNEUMO 23----1件: 65
470Pneumovax® (pneumococcal polysaccharide vaccine)----1件: 65
471Polyclonal IgG----1件: 65
472Posaconazole1件: Posaconazole1件: D02555 --4件: 60, 65, 96, 299
473Posaconazole (PSZ)1件: Posaconazole1件: D02555 --1件: 65
474PPS----1件: 65
475PREDNISOLONE1件: Prednisolone8件: D00472 ,
D00980 ,
D00981 ,
D00982 ,
D01239 ,
D01998 ,
D02156 ,
D03301
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬43件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
476Prednisone1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬48件: 2, 6, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331
477PREVENAR----1件: 65
478Prevenar® (7-valent pneumococcal conjugate vaccine)----1件: 65
479PRIVIGEN1件: Human immunoglobulin G---4件: 11, 14, 51, 65
480Privigen®1件: Human immunoglobulin G---3件: 14, 63, 65
481Procarbazine1件: Procarbazine2件: D00478 ,
D08423
--1件: 65
482Progynova 21 mite----1件: 65
483Proleukin1件: Aldesleukin1件: D00748 3件: IL2RA,
IL2RB,
IL2RG 💬
14件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬3件: 2, 49, 65
484PROLEUKIN® S1件: Aldesleukin1件: D00748 3件: IL2RA,
IL2RB,
IL2RG 💬
14件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬1件: 65
485Promacta1件: Eltrombopag---2件: 63, 65
486Prometic's Immune Globulin Intravenous 10%----1件: 65
487PSRS11.EFS.IL2RG.pre* retroviral vector----1件: 65
488PSRS11.EFS.IL2RG.pre* retroviral vector transduce----1件: 65
489PSRS11.EFS.IL2RG.pre* retroviral vector transduced cells----1件: 65
490PTH----2件: 65, 235
491PTH 1-341件: Teriparatide1件: D06078 1件: PTH1R 💬3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬2件: 65, 235
492Purified Vero Cell Vaccine)----1件: 65
493PYRIMETHAMINE1件: Pyrimethamine1件: D00488 --4件: 2, 4, 19, 65
494R-hIL-18BP----1件: 65
495Rabbit1件: Rabbit---8件: 11, 13, 49, 51, 60, 65, 96, 285
496Rabbit anti-thymocyte globulin1件: Rabbit---2件: 49, 65
497Radiation: radiation therapy----5件: 34, 60, 65, 284, 285
498Radiation: Total body 200cGy----1件: 65
499Radiation: Total Body Irradiation----7件: 36, 49, 51, 60, 65, 283, 284
500Radiation: Total Body Irradiation (TBI)----3件: 60, 65, 285
501Radiation: total-body irradiation----9件: 28, 51, 60, 62, 65, 96, 283, 284, 285
502RAG1 LV CD34+ cells----1件: 65
503Ranitidine1件: Ranitidine2件: D00422 ,
D00673
1件: HRH2 💬3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬2件: 13, 65
504Recombinant human hyaluronidase2件: Hyaluronidase,
Hyaluronidase (human recombinant)
3件: D04455 ,
D04456 ,
D06604
--3件: 14, 28, 65
505Recombinant Human Hyaluronidase (rHuPH20)2件: Hyaluronidase,
Hyaluronidase (human recombinant)
3件: D04455 ,
D04456 ,
D06604
--1件: 65
506Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)2件: Hyaluronidase,
Hyaluronidase (human recombinant)
3件: D04455 ,
D04456 ,
D06604
--1件: 65
507Recombinant human hyaluronidase + immune globulin intravenous2件: Hyaluronidase,
Hyaluronidase (human recombinant)
3件: D04455 ,
D04456 ,
D06604
--1件: 65
508Reduced Intensity Conditioning----2件: 19, 65
509Reduced Intensity Preparative Regimen----3件: 62, 65, 284
510Reduced Toxicity Ablative Regimen----3件: 62, 65, 284
511Release1件: Manganese citrate---12件: 6, 8, 13, 46, 65, 78, 81, 96, 97, 206, 226, 299
512Retroviral SF71-gp91phox transduced CD34+ cells----1件: 65
513Retrovirus-mediated gene transfer----1件: 65
514RhuCD40L----1件: 65
515RI-002----1件: 65
516Rifaximin1件: Rifaximin1件: D02554 --7件: 6, 65, 93, 96, 97, 99, 296
517Rimiducid1件: Rimiducid1件: D11195 1件: CASP9 💬35件: Alzheimer disease, Amyotrophic lateral sclerosis, Apoptosis, Apoptosis - multiple species, Colorectal cancer, Endometrial cancer, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Huntington disease, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Measles, Non-small cell lung cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parkinson disease, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Prion disease, Prostate cancer, Small cell lung cancer, Thyroid hormone signaling pathway, Toxoplasmosis, Tuberculosis, VEGF signaling pathway, Viral myocarditis, p53 signaling pathway 💬6件: 19, 60, 65, 284, 285, 326
518Rituximab1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬49件: 6, 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
519Rituximab (RTX) and Azathioprine (AZA)2件: Azathioprine,
Rituximab
3件: D00238 ,
D02994 ,
D03033
1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 65
520Rivogenlecleucel----6件: 19, 60, 65, 284, 285, 326
521Romiplostim1件: Romiplostim1件: D08990 1件: MPL 💬2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬4件: 60, 63, 64, 65
522RP-L201----1件: 65
523RTX----5件: 11, 46, 65, 222, 240
524SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)----1件: 65
525SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)----1件: 65
526SCID screening----1件: 65
527SCYX-71581件: SCYX-7158---1件: 65
528Sirolimus1件: Sirolimus1件: D00753 1件: MTOR 💬51件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬36件: 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 89, 98, 127, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331
529Sodium chloride2件: Chloride ion,
Sodium chloride
1件: D02056 --21件: 6, 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 67, 78, 96, 168, 193, 227, 228, 271, 288, 299
530Somatic gene-therapy by X-CGD----1件: 65
531Somatotropin1件: Somatotropin1件: D02691 1件: GHR 💬5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬4件: 3, 65, 78, 236
532Somatropin1件: Somatotropin1件: D02691 1件: GHR 💬5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬19件: 2, 3, 19, 46, 65, 74, 75, 78, 96, 107, 113, 187, 193, 195, 238, 265, 274, 276, 299
533Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate5件: Arginine,
Clonidine,
Estradiol,
Estradiol valerate,
Somatotropin
12件: D00105 ,
D00281 ,
D00604 ,
D01413 ,
D01617 ,
D01953 ,
D02691 ,
D02982 ,
D04061 ,
D04063 ,
D04064 ,
D04065
6件: ADRA2A,
ADRA2B,
ADRA2C,
ESR1,
ESR2,
GHR 💬
16件: Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway, cGMP-PKG signaling pathway 💬1件: 65
534STA-5326----2件: 65, 96
535Stelara (ustekinumab)1件: Ustekinumab1件: D09214 3件: IL12A,
IL12B,
IL23A 💬
28件: African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬1件: 65
536Stem Cell Infusion----5件: 28, 60, 65, 284, 285
537Stem Cell Transplant----6件: 19, 20, 60, 65, 164, 284
538Stem Cell Transplantation----13件: 13, 19, 20, 46, 51, 60, 62, 65, 90, 125, 164, 234, 326
539STRIMVELIS----1件: 65
540Subcuvia----3件: 14, 49, 65
541Subgam----1件: 65
542Sulfadoxine1件: Sulfadoxine1件: D00580 --1件: 65
543Suspension of autologous CD34+cells transduced with the G1XCGD viral vector----1件: 65
544T-Cell Depleted & CD34+Select/w/StemCell Enriched Product----1件: 65
545Tabelecleucel----1件: 65
546Tablets Fexinidazole1件: Fexinidazole1件: D11252 --1件: 65
547Tacrolimus1件: Tacrolimus2件: D00107 ,
D08556
5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬
33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
548Tacrolimus (Tacro)1件: Tacrolimus2件: D00107 ,
D08556
5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬
33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 65
549TADEKINIG ALFA1件: Tadekinig alfa---1件: 65
550TAK-771----2件: 14, 65
551TBX-1400----1件: 65
552TCR alfa beta T cell depletion----1件: 65
553Thalidomide1件: Thalidomide1件: D00754 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬20件: 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331
554Therapeutic allogeneic lymphocytes----3件: 60, 65, 285
555There is no recommended INN----1件: 65
556Thiotepa1件: Thiotepa1件: D00583 --12件: 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284, 285
557Thiotepa--escalated dose1件: Thiotepa1件: D00583 --4件: 19, 20, 65, 284
558Thiotepa--single daily dose1件: Thiotepa1件: D00583 --4件: 19, 20, 65, 284
559Thymafalsin----1件: 65
560THYMALFASIN1件: Thymalfasin1件: D06116 --1件: 65
561Thymoglobulin1件: Antithymocyte immunoglobulin (rabbit)---7件: 36, 51, 60, 65, 96, 285, 326
562Thymus Tissue for Transplantation----1件: 65
563Thymus/Parathyroid Transplantation----2件: 65, 235
564To be confirmed----3件: 46, 65, 97
565Tofacitinib1件: Tofacitinib1件: D09970 4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬15件: 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
566Total body Irradiation----6件: 19, 20, 51, 60, 65, 285
567Total lymphoid irradiation----3件: 65, 284, 326
568Traditional treatment of CGD and TB----1件: 65
569Transduced Lymphocytes----1件: 65
570Transduced patient CD34+ cells----1件: 65
571Transplant Conditioning with Mobilization and Alemtuzumab1件: Alemtuzumab1件: D02802 1件: CD52 💬-1件: 65
572Transplant Conditioning with Mobilization Only----1件: 65
573Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan4件: Alemtuzumab,
Fludarabine,
Melphalan,
Thiotepa
5件: D00369 ,
D00583 ,
D01907 ,
D02802 ,
D07966
2件: CD52,
RRM1 💬
-2件: 65, 164
574TREOSULFAN1件: Treosulfan1件: D07253 --6件: 13, 19, 62, 65, 283, 286
575Triheptanoin1件: Triheptanoin1件: D11465 --10件: 2, 8, 65, 149, 156, 248, 256, 257, 317, 324
576TYF-IL-2Rg gene-modified autologous stem cells----1件: 65
577Umbilical Cord Blood Transplantation----5件: 60, 65, 284, 285, 326
578Unrelated BM with T cell depletion----1件: 65
579Unrelated cord blood----1件: 65
580Unrelated PBSC with T cell depletion----1件: 65
581Ustekinumab1件: Ustekinumab1件: D09214 3件: IL12A,
IL12B,
IL23A 💬
28件: African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
582Valacyclovir1件: Valaciclovir3件: D00398 ,
D08664 ,
D10518
--1件: 65
583Valproic Acid1件: Valproic acid1件: D00399 7件: ABAT,
ALDH5A1,
CACNA1G,
CACNA1H,
CACNA1I,
GAD1,
GAD2 💬
17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬10件: 3, 5, 26, 34, 65, 89, 90, 222, 256, 331
584Verorab® (PVRV----1件: 65
585Vigantol----4件: 13, 65, 96, 97
586Vinblastine1件: Vinblastine2件: D01068 ,
D08675
9件: TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬
10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬2件: 34, 65
587Vinblastine, vincristine, prednisone, daunorubicin4件: Daunorubicin,
Prednisone,
Vinblastine,
Vincristine
7件: D00473 ,
D01068 ,
D01264 ,
D02197 ,
D07776 ,
D08675 ,
D08679
12件: NR3C1,
TOP2A,
TOP2B,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬
12件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Platinum drug resistance, Prion disease, Salmonella infection 💬1件: 65
588Vincristine1件: Vincristine2件: D02197 ,
D08679
9件: TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬
10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬4件: 26, 34, 65, 331
589Vitamin B3----2件: 65, 107
590Vitamin D31件: Cholecalciferol1件: D00188 1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬12件: 6, 13, 20, 46, 49, 51, 53, 60, 65, 96, 97, 299
591Vivaglobin----2件: 14, 65
592VM106----1件: 65
593Water1件: Water1件: D00001 --23件: 2, 5, 6, 13, 17, 19, 22, 35, 46, 51, 53, 56, 57, 63, 65, 67, 78, 84, 96, 97, 226, 278, 299
594X4P-001----1件: 65
595XELJANZ (tofacitinib)1件: Tofacitinib1件: D09970 4件: JAK1,
JAK2,
JAK3,
TYK2 💬
37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 65
596Xifaxan1件: Rifaximin1件: D02554 --2件: 65, 94
597Zadaxin----2件: 65, 299
598ZARZIO1件: Filgrastim1件: D03235 1件: CSF3R 💬5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬3件: 38, 65, 285
599Zoledronate1件: Zoledronic acid4件: D01968 ,
D06378 ,
D06379 ,
D08689
1件: FDPS 💬4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬2件: 46, 65